At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone
In Brief
A Phase 3 clinical trial evaluating Bortezomib, Dexamethasone, and 3 other interventions for Multiple Myeloma. Completed, enrolled 502 participants across 235 sites in 2 countries.
Detailed Summary
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Study Details
Timeline
Interventions
Bortezomib bolus intravenous (IV) injection
Dexamethasone for oral administration
Melphalan for oral administration
Prednisone for oral administration
Thalidomide for oral administration